SMTI - חוב כולל להון Sanara MedTech

Sanara MedTech Inc. (SMTI) supplies innovative biologics for surgery and tissue regeneration, ensuring high margins and a stable cash flow by integrating products into hospital protocols. The market valuation trend for the asset based on the Separate Debt/Total Equity ratio is 5.83. The business relies on government procurement of specialized agents, where distribution expansion and the proven efficacy of skin healing methods serve as key growth drivers.

Sanara MedTech Inc. develops high-tech solutions in the field of regenerative medicine. This indicator compares total liabilities to the net asset value of the owners. Analyzing the company's debt-to-equity ratio allows for an assessment of its financial leverage. Rising leverage increases the risk of default in the event of disruptions in the international logistics of biomaterials due to geopolitics. A stable trend confirms the resilience of the business's financing structure.